Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent

The patent specifically covers Ampligen in combination with Keytruda for treatment of various cancers.

Author Image

By: Patrick Lavery

Content Marketing Editor

Editor’s Take: Patents are crucial to protecting intellectual property, particularly in cancer immunotherapy.

AIM ImmunoTech was granted a patent from the United States Patent and Trademark Office for Ampligen (rintatolimod) until December 2039. The office issued the patent specific to Ampligen’s use in combination with the PD-1 checkpoint inhibitor pembrolizumab. Widely known as Keytruda (by Merck, or MSD outside the U.S. and Canada), pembrolizumab is an established cancer treatment.

Meanwhile, Ampligen, a wide-spectrum Toll-like receptor 3 (TLR3) agonist, has been investigated for treatment of various cancers and other conditions. AIM describes Ampligen as its lead product primarily for treatment of late-stage pancreatic cancer.

AIM ImmunoTech Patent Pursuit

This is not AIM’s first patent for the use of Ampligen as a cancer treatment, and additional applications are pending. One U.S. patent, expiring August 2039, covers Ampligen as a combination oncology therapy with an anti-programmed death-ligand 1 (PD-L1) antibody.

Patents combining Ampligen with PD-1 or PD-L1-related treatments additionally exist in the Netherlands and Japan.

Ampligen Indications May Expand

Despite AIM identifying Ampligen firstly as a pancreatic cancer treatment, the drug’s patent application—combined with pembrolizumab—expands vastly. Other patent claims: skin, colorectal, ovarian, breast, bladder, and lung cancers; melanoma; renal cell carcinoma; and head and neck tumors.

AIM ImmunoTech CEO Thomas Equels discussed the importance of patents in protecting intellectual property (IP) in cancer immunotherapy.

“[This] marks another significant step in building a broad and durable IP patent estate around Ampligen’s potential role,” Equels said. “This patent protects Ampligen’s use in combination therapy with the leading PD-1 checkpoint therapy across a broad range of cancers. It specifically encompasses pancreatic cancer, the central focus of our late-stage oncology strategy. We believe this growing patent estate strengthens both the scientific and strategic foundation supporting Ampligen’s long-term oncology opportunity.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics